Immuneering
IMRX
68 hedge funds and large institutions have $182M invested in Immuneering in 2025 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 4 closing their positions.
1,312% more capital invested
Capital invested by funds: $12.9M → $182M (+$169M)
725% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 4
229% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
74% more funds holding
Funds holding: 39 → 68 (+29)
52% more ownership
Funds ownership: 10.64% → 62.65% (+52%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$44.5M |
| 2 |
S
Sanofi
Paris,
France
|
+$14.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.34M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$7.87M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.57M |
| 2 |
Corient Private Wealth
Miami,
Florida
|
-$143K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$99.1K |
| 4 |
First Manhattan
New York
|
-$41.9K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$18.2K |
IMRX Hedge Fund Activity: Q3 2025 in Review
68 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q3 2025, worth a combined $182M — up 1,312% from $12.9M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IMRX positions and 4 closed out — a net gain of 29 holders — while 23 added to existing stakes and 7 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $44.5M. The largest seller was Marshall Wace, cutting an estimated $1.57M.
- 68 institutional investors held Immuneering (IMRX) as of Q3 2025, up from 39 in Q2 2025.
- Funds reported $182M of Immuneering stock for Q3 2025, up 1,312% quarter-over-quarter.
- 33 funds opened new Immuneering positions in Q3 2025 and 4 closed out, a net change of +29 holders.
- The largest Immuneering buyer in Q3 2025 was Fidelity Investments, an estimated $44.5M added.
- The largest Immuneering seller in Q3 2025 was Marshall Wace, an estimated $1.57M sold.
Based on aggregated 13F filings for Q3 2025.